Clune & Associates’s AbbVie ABBV Stock Holding History

Clune & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.79M	Sell	19,033 -298	-2%	-$64.1K	0.72%	35
2026 Q1	$4.2M	Buy	19,331 +895	+5%	+$199K	0.79%	36
2025 Q4	$4.21M	Buy	18,436 +419	+2%	+$95.4K	0.91%	36
2025 Q3	$4.17M	Sell	18,017 -85	-0.5%	-$17.3K	1.04%	30
2025 Q2	$3.36M	Sell	18,102 -1,151	-6%	-$214K	0.92%	34
2025 Q1	$4.03M	Buy	19,253 +90	+0.5%	+$17.5K	1.24%	23
2024 Q4	$3.41M	Buy	+19,163	New	+$3.52M	1.13%	26

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Clune & Associates's ABBV Position: Q2 2026 in Review

Clune & Associates reduced its AbbVie (ABBV) stake by 1.5% in Q2 2026, selling an estimated $64.1K and leaving 19,033 shares worth $4.79M. The position accounts for 0.72% of the portfolio, ranked #35.

Clune & Associates first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 1,042 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Clune & Associates held 19,033 shares of AbbVie worth $4.79M as of Q2 2026.
Clune & Associates sold 298 AbbVie shares in Q2 2026, an estimated $64.1K.
AbbVie made up 0.72% of Clune & Associates's portfolio in Q2 2026, its #35 holding.
Clune & Associates first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
1,042 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Clune & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.